Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

University of British Columbia

$27,750.00

Interspecies differences in glial secretions contributing to neuronal survival and death

EF 2008-09

Résumé
The neurodegenerative disorders of humans (e.g. Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis) and animals (e.g. scrapie, bovine spongiform encephalopathy) are characterised by irreversible loss of neurons. The non-neuronal cells in the brain, including microglia and astrocytes, can affect neuronal survival significantly. They do so by secreting various mediators that either enhance neuronal survival (i.e. neurotrophic factors) or cause neuronal death (i.e. neurotoxins). Furthermore, when these cells become activated, the repertoire of neuroactive molecules that they secrete may depend not only on the type of stimulus they encounter but also on the species of origin of the cells. Thus far, no systematic study has explored this aspect of glia-neuron signaling. Furthermore, there are glial mediators that have not been described yet. The proposed research will address these issues by studying secretions of microglial cells and astrocytes from humans and several other mammals, including rats, mice, pigs and sheep. I will analyse neuroactive products that are released by these cells after their exposure to several stimulants that are relevant to both human and animal neurodegenerative pathology and inflammatory mechanisms. I will also investigate the secretory arsenal of several glia-like cell lines to assess their usefulness as models of primary glial cells and I will search for novel, yet unidentified, neuroactive products of glial cells by using an unbiased proteomics technique. The proposed research program will answer a fundamental biological question about whether there are essential differences between glial cells from different species in their secretory responses to specific stimuli. An important practical application, crucial to an effective drug discovery process and translational research for human and animal neurodegenerative diseases, will be identification of the most appropriate in vitro model systems and species suitable for such research. These model systems could be used by other researchers to develop drugs with beneficial action in various neurodegenerative disorders of humans and animals, which could have substantial economic as well as health benefits to Canada.
Programme
Discovery Grants Program - Individual
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
356033-2008
Name nom
Klegeris, Andis
Department département
Okanagan - Biology & Physical Geography
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2008
Competition year année de concours
2008
Award amount
27750
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1011
Committee name en
Integrative Animal Biology
Committee name fr
Biologie Animale Intégrative
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5501
Research subject group en
Animal biology
Research subject group fr
Biologie animale
Research subject en
Neurophysiology
Research subject fr
Neurophysiologie
Partie
1
Nb partie
5
Application title
Interspecies differences in glial secretions contributing to neuronal survival and death
Keyword
NA
Application summary
The neurodegenerative disorders of humans (e.g. Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis) and animals (e.g. scrapie, bovine spongiform encephalopathy) are characterised by irreversible loss of neurons. The non-neuronal cells in the brain, including microglia and astrocytes, can affect neuronal survival significantly. They do so by secreting various mediators that either enhance neuronal survival (i.e. neurotrophic factors) or cause neuronal death (i.e. neurotoxins). Furthermore, when these cells become activated, the repertoire of neuroactive molecules that they secrete may depend not only on the type of stimulus they encounter but also on the species of origin of the cells. Thus far, no systematic study has explored this aspect of glia-neuron signaling. Furthermore, there are glial mediators that have not been described yet. The proposed research will address these issues by studying secretions of microglial cells and astrocytes from humans and several other mammals, including rats, mice, pigs and sheep. I will analyse neuroactive products that are released by these cells after their exposure to several stimulants that are relevant to both human and animal neurodegenerative pathology and inflammatory mechanisms. I will also investigate the secretory arsenal of several glia-like cell lines to assess their usefulness as models of primary glial cells and I will search for novel, yet unidentified, neuroactive products of glial cells by using an unbiased proteomics technique. The proposed research program will answer a fundamental biological question about whether there are essential differences between glial cells from different species in their secretory responses to specific stimuli. An important practical application, crucial to an effective drug discovery process and translational research for human and animal neurodegenerative diseases, will be identification of the most appropriate in vitro model systems and species suitable for such research. These model systems could be used by other researchers to develop drugs with beneficial action in various neurodegenerative disorders of humans and animals, which could have substantial economic as well as health benefits to Canada.